Although several clinical reports demonstrated a durable patency rate after a novel fluoropolymer-coated paclitaxel-eluting stent (Eluvia; Boston Scientific, Marlborough, MA, USA) placement, aneurysmal degeneration after drug-eluting stent (Eluvia) placement has raised clinical concerns. Here, we report a case with progressive aneurysm formation on serial angiography and intravascular ultrasound over 50 months after drug-eluting stent (Eluvia) placement for a superficial femoral artery atheromatous plaque. A 79-year-old woman with right leg intermittent claudication at 100 m distance was referred to our hospital. Pre-procedural angiography showed long-segment severe stenosis from the middle-to-distal part of the right superficial femoral artery, and a 7 mm wide drug-eluting stent (Eluvia) was placed. However, the patient had a recurrence of intermittent claudication in the right lower extremity 25 months thereafter. Angiography revealed de novo stenosis in the distal part of the popliteal artery and proximal superficial femoral artery in-stent restenosis. Subsequently, the patient underwent endovascular therapy for these lesions. In addition, intravascular ultrasound at the time of endovascular therapy revealed femoral artery enlargement with a maximum vessel diameter of 10.0 mm at the distal edge of the stent. Intermittent claudication on the right side recurred again 50 months after drug-eluting stent (Eluvia). Angiography demonstrated de novo severe stenosis from the distal part of the superficial femoral artery to the middle part of the popliteal artery. Peri-stent contrast staining was found at the distal part of the drug-eluting stent (Eluvia) site. Intravascular ultrasound showed a further enlargement of maximum vessel diameter to 12.0 mm at the distal edge of the stent. We report a case with progressive aneurysm degeneration on serial angiography and intravascular ultrasound over 50 months after drug-eluting stent (Eluvia) placement for a superficial femoral artery stenosis.

中文翻译：

---

股浅动脉中含氟聚合物涂层紫杉醇洗脱支架的动脉瘤变性：日益受到关注

尽管一些临床报告证明了新型含氟聚合物涂层紫杉醇洗脱支架（Eluvia；波士顿科学，Marlborough，MA，USA）放置后的持久通畅率，但药物洗脱支架（Eluvia）放置后的动脉瘤变性引起了临床关注。在这里，我们报告了一例在药物洗脱支架 (Eluvia) 置入浅表股动脉粥样斑块后 50 个月内，连续血管造影和血管内超声显示进行性动脉瘤形成的病例。一名 79 岁女性右腿间歇性跛行，距离 100 m 被转诊至我院。术前血管造影显示右股浅动脉中远段长段严重狭窄，置入 7 mm 宽药物洗脱支架（Eluvia）。然而，25 个月后，患者右下肢间歇性跛行复发。血管造影显示腘动脉远端和近端股浅动脉支架内再狭窄。随后，患者接受了这些病变的血管内治疗。此外，血管内治疗时的血管内超声显示支架远端的股动脉扩张，最大血管直径为 10.0 mm。药物洗脱支架（Eluvia）后 50 个月，右侧间歇性跛行再次复发。血管造影显示从股浅动脉远端到腘动脉中部有新发严重狭窄。在药物洗脱支架 (Eluvia) 部位的远端部分发现了支架周围对比染色。血管内超声显示支架远端的最大血管直径进一步扩大至 12.0 mm。我们报告了一例在药物洗脱支架 (Eluvia) 置入治疗股浅动脉狭窄后 50 个月内，连续血管造影和血管内超声显示进行性动脉瘤变性的病例。